<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39185419</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Vaccine and antiviral drug promise for preventing post-acute sequelae of COVID-19, and their combination for its treatment.</ArticleTitle><Pagination><StartPage>1329162</StartPage><MedlinePgn>1329162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1329162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1329162</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Most healthy individuals recover from acute SARS-CoV-2 infection, whereas a remarkable number continues to suffer from unexplained symptoms, known as Long COVID or post-acute COVID-19 syndrome (PACS). It is therefore imperative that methods for preventing and treating the onset of PASC be investigated with the utmost urgency.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A mathematical model of the immune response to vaccination and viral infection with SARS-CoV-2, incorporating immune memory cells, was developed.</AbstractText><AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="UNASSIGNED">Similar to our previous model, persistent infection was observed by the residual virus in the host, implying the possibility of chronic inflammation and delayed recovery from tissue injury. Pre-infectious vaccination and antiviral medication administered during onset can reduce the acute viral load; however, they show no beneficial effects in preventing persistent infection. Therefore, the impact of these treatments on the PASC, which has been clinically observed, is mainly attributed to their role in preventing severe tissue damage caused by acute viral infections. For PASC patients with persistent infection, vaccination was observed to cause an immediate rapid increase in viral load, followed by a temporary decrease over approximately one year. The former was effectively suppressed by the coadministration of antiviral medications, indicating that this combination is a promising treatment for PASC.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sumi and Harada.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sumi</LastName><ForeName>Tomonari</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Institute for Interdisciplinary Science, Okayama University, Okayama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, Okayama University, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Kouji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Engineering, Toyohashi University of Technology, Toyohashi, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for IT-Based Education, Toyohashi University of Technology, Toyohashi, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">antiviral drug</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">long Covid</Keyword><Keyword MajorTopicYN="N">mathematical model</Keyword><Keyword MajorTopicYN="N">persistent viruses</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39185419</ArticleId><ArticleId IdType="pmc">PMC11341427</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1329162</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. (2021) 4:e210830. doi:&#xa0;10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, et al. . Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:993&#x2013;8. doi:&#xa0;10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. . Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. (2021) 11:e048391. doi:&#xa0;10.1136/bmjopen-2020-048391</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Definition WCC. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2022) 22:E102&#x2013;7. doi:&#xa0;10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. doi:&#xa0;10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Yang L. Post-acute sequelae of SARS-CoV-2 infection: A neglected public health issue. Front Public Health. (2022) 10:908757. doi:&#xa0;10.3389/fpubh.2022.908757</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.908757</ArticleId><ArticleId IdType="pmc">PMC9247346</ArticleId><ArticleId IdType="pubmed">35784200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271&#x2013;280.e8. doi:&#xa0;10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. . Extrapulmonary manifestations of COVID-19. Nat Med. (2020) 26:1017&#x2013;32. doi:&#xa0;10.1038/s41591-020-0968-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles VG, L&#xfc;tgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. . Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. (2020) 383:590&#x2013;2. doi:&#xa0;10.1056/NEJMc2011400</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. (2020) 526:135&#x2013;40. doi:&#xa0;10.1016/j.bbrc.2020.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.03.044</ArticleId><ArticleId IdType="pmc">PMC7156119</ArticleId><ArticleId IdType="pubmed">32199615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes-Pacheco M, Silva PL, Cruz FF, Battaglini D, Robba C, Pelosi P, et al. . Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol. (2021) 12:593223. doi:&#xa0;10.3389/fphys.2021.593223</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.593223</ArticleId><ArticleId IdType="pmc">PMC7876335</ArticleId><ArticleId IdType="pubmed">33584343</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. (2021) 12:698169. doi:&#xa0;10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MS, Wang Z, Abdel-Mohsen M, Chen X, Montaner LJ. Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID. J Leukoc Biol. (2023) 113:236&#x2013;54. doi:&#xa0;10.1093/jleuko/qiac001</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jleuko/qiac001</ArticleId><ArticleId IdType="pubmed">36807444</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. (2022) 375:1122. doi:&#xa0;10.1126/science.abm8108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. (2023) 23:618&#x2013;34. doi:&#xa0;10.1038/s41577-023-00904-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, Cox TO, Dohnalov&#xe1; L, Litichevskiy L, et al. . Serotonin reduction in post-acute sequelae of viral infection. Cell. (2023) 186:4851&#x2013;4867.e20. doi:&#xa0;10.1016/j.cell.2023.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi T, Harada K. Immune response to SARS-CoV-2 in severe disease and long COVID-19. iScience. (2022) 25:104723. doi:&#xa0;10.1016/j.isci.2022.104723</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104723</ArticleId><ArticleId IdType="pmc">PMC9251893</ArticleId><ArticleId IdType="pubmed">35813874</ArticleId></ArticleIdList></Reference><Reference><Citation>Du SQ, Yuan W. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis. J Med Virol. (2020) 92:1615&#x2013;28. doi:&#xa0;10.1002/jmv.25866</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25866</ArticleId><ArticleId IdType="pmc">PMC7267673</ArticleId><ArticleId IdType="pubmed">32356908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Vargas EA, Velasco-Hernandez JX. In-host mathematical modelling of COVID-19 in humans. Annu Rev Control. (2020) 50:448&#x2013;56. doi:&#xa0;10.1016/j.arcontrol.2020.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcontrol.2020.09.006</ArticleId><ArticleId IdType="pmc">PMC7526677</ArticleId><ArticleId IdType="pubmed">33020692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahoo S, Jhunjhunwala S, Jolly MK. The good, the bad and the ugly: A mathematical model investigates the differing outcomes among CoVID-19 patients. J Indian Inst Sci. (2020) 100:673&#x2013;81. doi:&#xa0;10.1007/s41745-020-00205-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41745-020-00205-1</ArticleId><ArticleId IdType="pmc">PMC7533167</ArticleId><ArticleId IdType="pubmed">33041543</ArticleId></ArticleIdList></Reference><Reference><Citation>Perelson AS, Ke R. Mechanistic modeling of SARS-CoV-2 and other infectious diseases and the effects of therapeutics. Clin Pharmacol Ther. (2021) 109:829&#x2013;40. doi:&#xa0;10.1002/cpt.2160</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2160</ArticleId><ArticleId IdType="pmc">PMC8142935</ArticleId><ArticleId IdType="pubmed">33410134</ArticleId></ArticleIdList></Reference><Reference><Citation>Almocera AES, Quiroz G, Hernandez-Vargas EA. Stability analysis in COVID-19 within-host model with immune response. Commun Nonlinear Sci Numer Simul. (2021) 95:105584. doi:&#xa0;10.1016/j.cnsns.2020.105584</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnsns.2020.105584</ArticleId><ArticleId IdType="pmc">PMC7606083</ArticleId><ArticleId IdType="pubmed">33162723</ArticleId></ArticleIdList></Reference><Reference><Citation>Challenger JD, Foo CY, Wu Y, Yan AWC, Marjaneh MM, Liew F, et al. . Modelling upper respiratory viral load dynamics of SARS-CoV-2. BMC Med. (2022) 20:25. doi:&#xa0;10.1186/s12916-021-02220-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02220-0</ArticleId><ArticleId IdType="pmc">PMC8755404</ArticleId><ArticleId IdType="pubmed">35022051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejima K, Kim KS, Ludema C, Bento AI, Iwanami S, Fujita Y, et al. . Estimation of the incubation period of COVID-19 using viral load data. Epidemics. (2021) 35:100454. doi:&#xa0;10.1016/j.epidem.2021.100454</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2021.100454</ArticleId><ArticleId IdType="pmc">PMC7959696</ArticleId><ArticleId IdType="pubmed">33773195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh I. Within host dynamics of SARS-CoV-2 in humans - modeling immune responses and antiviral treatments. SN Comput Sci. (2021) 2:482. doi:&#xa0;10.1007/s42979-021-00919-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42979-021-00919-8</ArticleId><ArticleId IdType="pmc">PMC8506088</ArticleId><ArticleId IdType="pubmed">34661166</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Ejima K, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, et al. . A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PloS Biol. (2021) 19:e3001128. doi:&#xa0;10.1371/journal.pbio.3001128</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001128</ArticleId><ArticleId IdType="pmc">PMC7984623</ArticleId><ArticleId IdType="pubmed">33750978</ArticleId></ArticleIdList></Reference><Reference><Citation>Moses ME, Hofmeyr S, Cannon JL, Andrews A, Gridley R, Hinga M, et al. . Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection. PloS Comput Biol. (2021) 17:e1009735. doi:&#xa0;10.1371/journal.pcbi.1009735</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009735</ArticleId><ArticleId IdType="pmc">PMC8740970</ArticleId><ArticleId IdType="pubmed">34941862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath BJ, Dehingia K, Mishra VN, Chu Y-M, Sarmah HK. Mathematical analysis of a within-host model of SARS-CoV-2. Adv Differ Equ. (2021) 2021:113&#x2013;11. doi:&#xa0;10.1186/s13662-021-03276-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13662-021-03276-1</ArticleId><ArticleId IdType="pmc">PMC7888694</ArticleId><ArticleId IdType="pubmed">33619433</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis RF, Pigozzo AB, Bonin CRB, Quintela B de M, Pompei LT, Vieira AC, et al. . A validated mathematical model of the cytokine release syndrome in severe COVID-19. Front Mol Biosci. (2021) 8:639423. doi:&#xa0;10.3389/fmolb.2021.639423</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.639423</ArticleId><ArticleId IdType="pmc">PMC8329239</ArticleId><ArticleId IdType="pubmed">34355020</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutouri C, Nikmaneshi MR, Hardin CC, Patel AB, Verma A, Khandekar MJ, et al. . In silico dynamics of COVID-19 phenotypes for optimizing clinical management. Proc Natl Acad Sci USA. (2021) 118:e2021642118. doi:&#xa0;10.1073/pnas.2021642118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021642118</ArticleId><ArticleId IdType="pmc">PMC7826337</ArticleId><ArticleId IdType="pubmed">33402434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadria M, Layton AT. Modeling within-host SARS-CoV-2 infection dynamics and potential treatments. Viruses. (2021) 13:1141. doi:&#xa0;10.3390/v13061141</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061141</ArticleId><ArticleId IdType="pmc">PMC8231802</ArticleId><ArticleId IdType="pubmed">34198530</ArticleId></ArticleIdList></Reference><Reference><Citation>Grebennikov D, Karsonova A, Loguinova M, Casella V, Meyerhans A, Bocharov G. Predicting the kinetic coordination of immune response dynamics in SARS-CoV-2 infection: implications for disease pathogenesis. Mathematics. (2022) 10:3154. doi:&#xa0;10.3390/math10173154</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/math10173154</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonyushkin VN, Akberdin IR, Kozlova YN, Schukin IA, Mironova TE, Bobikova AS, et al. . Multicompartmental mathematical model of SARS-CoV-2 distribution in human organs and their treatment. Mathematics. (2022) 10:1925. doi:&#xa0;10.3390/math10111925</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/math10111925</ArticleId></ArticleIdList></Reference><Reference><Citation>Elaiw AM, Alsaedi AJ, Hobiny AD, Aly S. Stability of a delayed SARS-CoV-2 reactivation model with logistic growth and adaptive immune response. Physica A. (2023) 616:128604. doi:&#xa0;10.1016/j.physa.2023.128604</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physa.2023.128604</ArticleId><ArticleId IdType="pmc">PMC9957504</ArticleId><ArticleId IdType="pubmed">36909816</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee AN, Basir FA, Biswas D, Abraha T. Global dynamics of SARS-CoV-2 infection with antibody response and the impact of impulsive drug therapy. Vaccines (Basel). (2022) 10:1846. doi:&#xa0;10.3390/vaccines10111846</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10111846</ArticleId><ArticleId IdType="pmc">PMC9699126</ArticleId><ArticleId IdType="pubmed">36366355</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal A, Duke ER, Cardozo-Ojeda EF, Schiffer JT. Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques. iScience. (2022) 25:104448. doi:&#xa0;10.1016/j.isci.2022.104448</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104448</ArticleId><ArticleId IdType="pmc">PMC9130309</ArticleId><ArticleId IdType="pubmed">35634576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejima K, Kim KS, Bento AI, Iwanami S, Fujita Y, Aihara K, et al. . Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study. BMC Infect Dis. (2022) 22:656&#x2013;9. doi:&#xa0;10.1186/s12879-022-07646-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07646-2</ArticleId><ArticleId IdType="pmc">PMC9331019</ArticleId><ArticleId IdType="pubmed">35902832</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wu J, Zhang J, Tang L, Mei H, Hu Y, et al. . A multicompartment mathematical model based on host immunity for dissecting COVID-19 heterogeneity. Heliyon. (2022) 8:e09488. doi:&#xa0;10.1016/j.heliyon.2022.e09488</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2022.e09488</ArticleId><ArticleId IdType="pmc">PMC9116108</ArticleId><ArticleId IdType="pubmed">35600458</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury SMEK, Chowdhury JT, Ahmed SF, Agarwal P, Badruddin IA, Kamangar S. Mathematical modelling of COVID-19 disease dynamics: Interaction between immune system and SARS-CoV-2 within host. MATH. (2022) 7:2618&#x2013;33. doi:&#xa0;10.3934/math.2022147</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/math.2022147</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Wei D, Zhang H, Demongeot J. A novel mathematical model that predicts the protection time of SARS-CoV-2 antibodies. Viruses. (2023) 15:586. doi:&#xa0;10.3390/v15020586</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020586</ArticleId><ArticleId IdType="pmc">PMC9962246</ArticleId><ArticleId IdType="pubmed">36851801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattaf K, Karimi El MI, Mohsen AA, Hajhouji Z, Younoussi El M, Yousfi N. Mathematical modeling and analysis of the dynamics of RNA viruses in presence of immunity and treatment: A case study of SARS-CoV-2. Vaccines (Basel). (2023) 11:201. doi:&#xa0;10.3390/vaccines11020201</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020201</ArticleId><ArticleId IdType="pmc">PMC9959189</ArticleId><ArticleId IdType="pubmed">36851079</ArticleId></ArticleIdList></Reference><Reference><Citation>dePillis L, Caffrey R, Chen G, Dela MD, Eldevik L, McConnell J, et al. . A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination. J Theor Biol. (2023) 556:111280. doi:&#xa0;10.1016/j.jtbi.2022.111280</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2022.111280</ArticleId><ArticleId IdType="pmc">PMC9529354</ArticleId><ArticleId IdType="pubmed">36202234</ArticleId></ArticleIdList></Reference><Reference><Citation>Voutouri C, Hardin CC, Naranbhai V, Nikmaneshi MR, Khandekar MJ, Gainor JF, et al. . Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2. Proc Natl Acad Sci USA. (2023) 120:e2211132120. doi:&#xa0;10.1073/pnas.2211132120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2211132120</ArticleId><ArticleId IdType="pmc">PMC9934028</ArticleId><ArticleId IdType="pubmed">36623200</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H, Yuan Z, Liu S, Jin Z, Sun G. Mathematical modeling the dynamics of SARS-CoV-2 infection with antibody-dependent enhancement. Nonlinear Dyn. (2023) 111:2943&#x2013;58. doi:&#xa0;10.1007/s11071-022-07939-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11071-022-07939-w</ArticleId><ArticleId IdType="pmc">PMC9540275</ArticleId><ArticleId IdType="pubmed">36246668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Agyeman AA, Hadjichrysanthou C, Standing JF. SARS-CoV-2 viral dynamic modeling to inform model selection and timing and efficacy of antiviral therapy. CPT Pharmacomet Syst Pharmacol. (2023) 12:1450&#x2013;60. doi:&#xa0;10.1002/psp4.13022</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.13022</ArticleId><ArticleId IdType="pmc">PMC10583246</ArticleId><ArticleId IdType="pubmed">37534815</ArticleId></ArticleIdList></Reference><Reference><Citation>Marc A, Marlin R, Donati F, Prague M, Kerioui M, H&#xe9;rate C, et al. . Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates. PloS Comput Biol. (2023) 19:e1010721. doi:&#xa0;10.1371/journal.pcbi.1010721</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1010721</ArticleId><ArticleId IdType="pmc">PMC10441782</ArticleId><ArticleId IdType="pubmed">37556476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranard BL, Chow CC, Megjhani M, Asgari S, Park S, Vodovotz Y. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound. J Med Virol. (2023) 95:e28854. doi:&#xa0;10.1002/jmv.28854</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28854</ArticleId><ArticleId IdType="pmc">PMC10264150</ArticleId><ArticleId IdType="pubmed">37287404</ArticleId></ArticleIdList></Reference><Reference><Citation>Elaiw AM, Alsaedi AJ, Hobiny AD. Global stability of a delayed SARS-CoV-2 reactivation model with logistic growth, antibody immunity and general incidence rate. Alexandria Eng J. (2022) 61:12475&#x2013;95. doi:&#xa0;10.1016/j.aej.2022.05.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aej.2022.05.034</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F, et al. . COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. (2021) 13:eabf8396. doi:&#xa0;10.1126/scitranslmed.abf8396</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature. (2021) 591:639&#x2013;44. doi:&#xa0;10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, R&#xf6;ssler A, et al. . Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. (2022) 163:495&#x2013;506.e8. doi:&#xa0;10.1053/j.gastro.2022.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. . Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. (2022) 3:371&#x2013;387.e9. doi:&#xa0;10.1016/j.medj.2022.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani R, Zentilin L, Correa R, Colliva A, Silvestri F, Zacchigna S, et al. . Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19. J Pathol. (2023) 259:254&#x2013;63. doi:&#xa0;10.1002/path.6035</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.6035</ArticleId><ArticleId IdType="pmc">PMC10107739</ArticleId><ArticleId IdType="pubmed">36651103</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. . Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. (2022) 76:e487&#x2013;e490. doi:&#xa0;10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm LK, Nielsen SSF, Pahus MH, Frattari GS, Olesen R, Andersen R, et al. . SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. (2021) 64:103230. doi:&#xa0;10.1016/j.ebiom.2021.103230</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103230</ArticleId><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz A, Mendes-Frias A, Azarias-da-Silva M, Andr&#xe9; S, Oliveira AI, Pires O, et al. . Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+&#x3b2;7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nat Commun. (2023) 14:1772&#x2013;14. doi:&#xa0;10.1038/s41467-023-37368-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37368-1</ArticleId><ArticleId IdType="pmc">PMC10061413</ArticleId><ArticleId IdType="pubmed">36997530</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-G&#xf3;mez A, Vitall&#xe9; J, Gasca-Capote C, Gutierrez-Valencia A, Trujillo-Rodriguez M, Serna-Gallego A, et al. . Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. (2021) 18:2128&#x2013;39. doi:&#xa0;10.1038/s41423-021-00728-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00728-2</ArticleId><ArticleId IdType="pmc">PMC8294321</ArticleId><ArticleId IdType="pubmed">34290398</ArticleId></ArticleIdList></Reference><Reference><Citation>Winheim E, Rinke L, Lutz K, Reischer A, Leutbecher A, Wolfram L, et al. . Impaired function and delayed regeneration of dendritic cells in COVID-19. PloS Pathog. (2021) 17:e1009742. doi:&#xa0;10.1371/journal.ppat.1009742</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009742</ArticleId><ArticleId IdType="pmc">PMC8523079</ArticleId><ArticleId IdType="pubmed">34614036</ArticleId></ArticleIdList></Reference><Reference><Citation>Clairon Q, Prague M, Planas D, Bruel T, Hocqueloux L, Prazuck T, et al. . Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2. PloS Comput Biol. (2023) 19:e1011282. doi:&#xa0;10.1371/journal.pcbi.1011282</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1011282</ArticleId><ArticleId IdType="pmc">PMC10434962</ArticleId><ArticleId IdType="pubmed">37549192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholami S, Korosec CS, Farhang-Sardroodi S, Dick DW, Craig M, Ghaemi MS, et al. . A mathematical model of protein subunits COVID-19 vaccines. Math Biosci. (2023) 358:108970. doi:&#xa0;10.1016/j.mbs.2023.108970</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mbs.2023.108970</ArticleId><ArticleId IdType="pmc">PMC9911981</ArticleId><ArticleId IdType="pubmed">36773843</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, et al. . Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Vaccine. (2022) 40:5631&#x2013;40. doi:&#xa0;10.1016/j.vaccine.2022.08.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.018</ArticleId><ArticleId IdType="pmc">PMC9376311</ArticleId><ArticleId IdType="pubmed">36028457</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol. (2007) 96:179&#x2013;204. doi:&#xa0;10.1016/S0065-2776(07)96005-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-2776(07)96005-8</ArticleId><ArticleId IdType="pubmed">17981207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn F, Ravetch JV. Fc&#x3b3; receptors as regulators of immune responses. Nat Rev Immunol. (2008) 8:34&#x2013;47. doi:&#xa0;10.1038/nri2206</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2206</ArticleId><ArticleId IdType="pubmed">18064051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. . Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. (2014) 15:707&#x2013;16. doi:&#xa0;10.1038/ni.2939</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2939</ArticleId><ArticleId IdType="pmc">PMC7430760</ArticleId><ArticleId IdType="pubmed">25045879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, et al. . Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. (2021) 32:100734. doi:&#xa0;10.1016/j.eclinm.2021.100734</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100734</ArticleId><ArticleId IdType="pmc">PMC7877219</ArticleId><ArticleId IdType="pubmed">33589882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura D. Mechanisms for the regulation of memory B-cell recall responses in mice. Int Immunol. (2021) 33:791&#x2013;6. doi:&#xa0;10.1093/intimm/dxab042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxab042</ArticleId><ArticleId IdType="pubmed">34279036</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nat Rev Immunol. (2020) 20:229&#x2013;38. doi:&#xa0;10.1038/s41577-019-0244-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0244-2</ArticleId><ArticleId IdType="pmc">PMC7223087</ArticleId><ArticleId IdType="pubmed">31836872</ArticleId></ArticleIdList></Reference><Reference><Citation>Low JS, Farsakoglu Y, Amezcua Vesely MC, Sefik E, Kelly JB, Harman CCD, et al. . Tissue-resident memory T cell reactivation by diverse antigen-presenting cells imparts distinct functional responses. J Exp Med. (2020) 217:e20192291. doi:&#xa0;10.1084/jem.20192291</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20192291</ArticleId><ArticleId IdType="pmc">PMC7398161</ArticleId><ArticleId IdType="pubmed">32525985</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F, Srivastava K, Simon V. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. (2021) 384:1372&#x2013;4. doi:&#xa0;10.1056/NEJMc2101667</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2101667</ArticleId><ArticleId IdType="pmc">PMC8008743</ArticleId><ArticleId IdType="pubmed">33691060</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. (2022) 53:101624. doi:&#xa0;10.1016/j.eclinm.2022.101624</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: A case series. Ann Intern Med. (2021) 174:1334&#x2013;6. doi:&#xa0;10.7326/M21-1976</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1976</ArticleId><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaber T, Ashish A, Unsworth A, Martindale J. Are mRNA covid 19 vaccines safe in long covid patients? A health care workers perspective. Br J Med Practition. (2021) 14:e008. doi:&#xa0;10.1016/j.vaccine.2020.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.10.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. . Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. (2022) 377:e069676. doi:&#xa0;10.1136/bmj-2021-069676</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain WD, Sherwood O, Banerjee A, van der Togt V, Hishmeh L, Rossman J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines (Basel). (2022) 10:652. doi:&#xa0;10.3390/vaccines10050652</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. J Med Virol. (2022) 94:3416&#x2013;20. doi:&#xa0;10.1002/jmv.27689</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27689</ArticleId><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E, Han AX, Boyd A, van Willigen HDG, Verveen A, Lebbink R, et al. . The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine. (2022) 40:4424&#x2013;31. doi:&#xa0;10.1016/j.vaccine.2022.05.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. (2022) 28:1461&#x2013;7. doi:&#xa0;10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ Med. (2023) 2:e000229. doi:&#xa0;10.1136/bmjmed-2022-000229</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000229</ArticleId><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. (2022) 103:154&#x2013;62. doi:&#xa0;10.1016/j.bbi.2022.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: A multicenter study from a large national health research network. Open Forum Infect Dis. (2022) 9:ofac228. doi:&#xa0;10.1093/ofid/ofac228</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Salamun J, Jacquerioz F, Courvoisier DS, Spechbach H, et al. . Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2. J Gen Intern Med. (2022) 37:1585&#x2013;8. doi:&#xa0;10.1007/s11606-022-07443-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07443-2</ArticleId><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. (2023) 183:554&#x2013;564. doi:&#xa0;10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, et al. . Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. (2022) 28:1042&#x2013;9. doi:&#xa0;10.1038/s41591-022-01739-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01739-w</ArticleId><ArticleId IdType="pmc">PMC9117133</ArticleId><ArticleId IdType="pubmed">35241844</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, Krishnamachary B, Ram AK, Kumar A, et al. . Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol. (2023) 95:e28568. doi:&#xa0;10.1002/jmv.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28568</ArticleId><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T, Wu X, Wen W, Lan P. Gut microbiome alterations in COVID-19. Genom Proteomics Bioinf. (2021) 19:679&#x2013;88. doi:&#xa0;10.1016/j.gpb.2021.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2021.09.004</ArticleId><ArticleId IdType="pmc">PMC8478109</ArticleId><ArticleId IdType="pubmed">34560321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusakabe T, Lin W-Y, Cheong J-G, Singh G, Ravishankar A, Yeung ST, et al. . Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19. Nat Immunol. (2023) 24:1879&#x2013;89. doi:&#xa0;10.1038/s41590-023-01637-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01637-4</ArticleId><ArticleId IdType="pmc">PMC10805066</ArticleId><ArticleId IdType="pubmed">37872315</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC-Y, Ng SSS, et al. . Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. (2022) 71:544&#x2013;52. doi:&#xa0;10.1136/gutjnl-2021-325989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Dweep H, Yin X, Wang H, Damra M, Goldman AR, et al. . Plasma markers of disrupted gut permeability in severe COVID-19 patients. Front Immunol. (2021) 12:686240. doi:&#xa0;10.3389/fimmu.2021.686240</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686240</ArticleId><ArticleId IdType="pmc">PMC8219958</ArticleId><ArticleId IdType="pubmed">34177935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. . SARS-CoV-2 productively infects human gut enterocytes. Science. (2020) 369:50&#x2013;4. doi:&#xa0;10.1126/science.abc1669</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, et al. . Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-&#x3ba;B signaling. JCI Insight. (2022) 7:e160989. doi:&#xa0;10.1172/jci.insight.160989</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.160989</ArticleId><ArticleId IdType="pmc">PMC9675436</ArticleId><ArticleId IdType="pubmed">36134654</ArticleId></ArticleIdList></Reference><Reference><Citation>Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. (2022) 185:3652&#x2013;70. doi:&#xa0;10.1016/j.cell.2022.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.08.026</ArticleId><ArticleId IdType="pmc">PMC9529843</ArticleId><ArticleId IdType="pubmed">36113467</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to epstein-barr virus reactivation. Pathogens. (2021) 10:763. doi:&#xa0;10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int. (2022) 42:1523&#x2013;30. doi:&#xa0;10.1007/s00296-022-05146-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau T-M, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. . Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. (2023) 133:e163669. doi:&#xa0;10.1172/JCI163669</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, et al. . Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. (2020) 369:1210&#x2013;20. doi:&#xa0;10.1126/science.abc6261</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvedaraite E, Hertwig L, Sinha I, Ponzetta A, Hed Myrberg I, Lourda M, et al. . Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. Proc Natl Acad Sci USA. (2021) 118:e2018587118. doi:&#xa0;10.1073/pnas.2018587118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2018587118</ArticleId><ArticleId IdType="pmc">PMC8017719</ArticleId><ArticleId IdType="pubmed">33479167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Kulzhabayeva D, Rodrigues NB, Di Vincenzo JD, Gill H, Subramaniapillai M, et al. . COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain Behav Immun. (2023) 111:211&#x2013;29. doi:&#xa0;10.1016/j.bbi.2023.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.03.022</ArticleId><ArticleId IdType="pmc">PMC10067136</ArticleId><ArticleId IdType="pubmed">36990297</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Mercad&#xe9;-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, et al. . The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. (2024) 12:225&#x2013;236. doi:&#xa0;10.1016/S2213-2600(23)00414-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. (2020) 370:1339. doi:&#xa0;10.1126/science.abe1107</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe1107</ArticleId><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald-Bocarsly P, Feng D. The role of type I interferon production by dendritic cells in host defense. Biochimie. (2007) 89:843&#x2013;55. doi:&#xa0;10.1016/j.biochi.2007.04.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2007.04.018</ArticleId><ArticleId IdType="pmc">PMC2752847</ArticleId><ArticleId IdType="pubmed">17544561</ArticleId></ArticleIdList></Reference><Reference><Citation>Makris S, Paulsen M, Johansson C. Type I interferons as regulators of lung inflammation. Front Immunol. (2017) 8:259. doi:&#xa0;10.3389/fimmu.2017.00259</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00259</ArticleId><ArticleId IdType="pmc">PMC5344902</ArticleId><ArticleId IdType="pubmed">28344581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PloS Pathog. (2020) 16:e1008737. doi:&#xa0;10.1371/journal.ppat.1008737</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008737</ArticleId><ArticleId IdType="pmc">PMC7390284</ArticleId><ArticleId IdType="pubmed">32726355</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan V, Hawks S, Crawford MA, Lehman CW, Morrison HA, Ivester HM, et al. . The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner. Viruses. (2021) 13:1062. doi:&#xa0;10.3390/v13061062</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061062</ArticleId><ArticleId IdType="pmc">PMC8226769</ArticleId><ArticleId IdType="pubmed">34205098</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean AJ, Richmond N, Koneva L, Attar M, Medina CAP, Thornton EE, et al. . Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites. Immunity. (2022) 55:718&#x2013;733.e8. doi:&#xa0;10.1016/j.immuni.2022.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.03.003</ArticleId><ArticleId IdType="pmc">PMC9044924</ArticleId><ArticleId IdType="pubmed">35349789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenm&#xfc;ller W, Brandes M, Wang Z, Herz J, Egen JG, Germain RN. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. Immunity. (2013) 38:502&#x2013;13. doi:&#xa0;10.1016/j.immuni.2012.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.11.012</ArticleId><ArticleId IdType="pmc">PMC3793246</ArticleId><ArticleId IdType="pubmed">23352234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman HD, Reynoso GV, Ngudiankama BF, Cush SS, Gibbs J, Bennink JR, et al. . CXCR3 chemokine receptor enables local CD8+ T cell migration for the destruction of virus-infected cells. Immunity. (2015) 42:524&#x2013;37. doi:&#xa0;10.1016/j.immuni.2015.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.02.009</ArticleId><ArticleId IdType="pmc">PMC4365427</ArticleId><ArticleId IdType="pubmed">25769612</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol. (2012) 12:136&#x2013;48. doi:&#xa0;10.1038/nri3152</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3152</ArticleId><ArticleId IdType="pmc">PMC3764486</ArticleId><ArticleId IdType="pubmed">22266691</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology. (2011) 132:466&#x2013;74. doi:&#xa0;10.1111/imm.2011.132.issue-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.2011.132.issue-4</ArticleId><ArticleId IdType="pmc">PMC3075500</ArticleId><ArticleId IdType="pubmed">21320124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity. (2009) 31:491&#x2013;501. doi:&#xa0;10.1016/j.immuni.2009.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.07.005</ArticleId><ArticleId IdType="pubmed">19733096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann FT, Hoops S, Klahn B, Kummer U, Mendes P, Pahle J, et al. . COPASI and its applications in biotechnology. J Biotechnol. (2017) 261:215&#x2013;20. doi:&#xa0;10.1016/j.jbiotec.2017.06.1200</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2017.06.1200</ArticleId><ArticleId IdType="pmc">PMC5623632</ArticleId><ArticleId IdType="pubmed">28655634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>